Patents by Inventor Patrick Burnett

Patrick Burnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS
    Publication number: 20250090509
    Abstract: Methods of treating a skin disorder or condition, including psoriasis, atopic dermatitis, and seborrheic dermatitis, in a patient by topically administering to the patient a pharmaceutical composition comprising roflumilast. The methods rapidly (e.g., within 24 or 48 hours) reduce itch experienced by a patient, for example itch as measured by the Worst Itch Numerical Rating Scale (WI-NRS). The method can also reduce itch as measured by the WI-NRS by 4 or more points.
    Type: Application
    Filed: September 13, 2024
    Publication date: March 20, 2025
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David Reuben BERK, Patrick Burnett, David Chu, Howard Welgus
  • METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS
    Publication number: 20250090508
    Abstract: Methods of treating a skin disorder or condition, including psoriasis, atopic dermatitis, and seborrheic dermatitis, in a patient by topically administering to the patient a pharmaceutical composition comprising roflumilast. The methods rapidly (e.g., within 24 or 48 hours) reduce itch experienced by a patient, for example itch as measured by the Worst Itch Numerical Rating Scale (WI-NRS). The method can also reduce itch as measured by the WI-NRS by 4 or more points.
    Type: Application
    Filed: September 13, 2024
    Publication date: March 20, 2025
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David Reuben BERK, Patrick Burnett, David Chu, Howard Welgus
  • DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONS
    Publication number: 20250082618
    Abstract: Methods of treating a skin disorder or condition in a patient by topically administering to the patient a pharmaceutical composition comprising roflumilast. The methods of treatment include administering the roflumilast composition once a day for a period of time followed by administering the roflumilast composition twice weekly as a maintenance dosing regimen.
    Type: Application
    Filed: September 6, 2024
    Publication date: March 13, 2025
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David Reuben BERK, Patrick Burnett, David Chu